Bio Medica Laboratories Share Price & Earnings Call Analysis
- Market cap
- ₹182 Cr
- P/E
- 15.32
- ROE
- 57.66%
- Price to sales
- 4.23
- Debt to equity
- 1.51
- EBITDA margin
- 45.67%
- Net profit margin
- 27.59%
- Promoter holding
- 67.70%
- Sales (last year)
- ₹43 Cr
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Bio Medica Lab.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Bio Medica Lab
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Bio Medica Lab
Shareholding breakup across reporting periods.
| May 2026 | |
|---|---|
| Promoters + | 67.70% |
| FIIs + | 0.29% |
| DIIs + | 2.31% |
| Public + | 29.71% |
| No. of Shareholders | 1,195 |
Financials of Bio Medica Lab
Quarterly Results
Quarter-by-quarter operating performance
Financials of Bio Medica Lab
Profit & Loss
Annual income statement trend
| Mar 2026 | |
|---|---|
| Sales + | 43 |
| Expenses + | 23 |
| Operating Profit | 20 |
| OPM % | 46% |
| Other Income + | 0 |
| Interest | 2 |
| Depreciation | 1 |
| Profit before tax | 16 |
| Tax % | 27% |
| Net Profit + | 12 |
| EPS in Rs | 13.06 |
| Dividend Payout % | 0% |
Financials of Bio Medica Lab
Balance Sheet
Capital structure and asset base
| Mar 2026 | |
|---|---|
| Equity Capital | 9 |
| Reserves | 17 |
| Borrowings + | 40 |
| Other Liabilities + | 7 |
| Total Liabilities | 73 |
| Fixed Assets + | 17 |
| CWIP | 0 |
| Investments | 0 |
| Other Assets + | 56 |
| Total Assets | 73 |
Financials of Bio Medica Lab
Cash Flows
Operating, investing and financing cash movement
| Mar 2026 | |
|---|---|
| Cash from Operating Activity + | -6 |
| Cash from Investing Activity + | -2 |
| Cash from Financing Activity + | 8 |
| Net Cash Flow | 0 |
| Free Cash Flow | -8 |
| CFO/OP | -9% |
Financials of Bio Medica Lab
Ratios
Working capital efficiency and return ratios
| Mar 2026 | |
|---|---|
| Debtor Days | 92 |
| Inventory Days | 759 |
| Days Payable | 116 |
| Cash Conversion Cycle | 735 |
| Working Capital Days | 300 |
| ROCE % |
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.